FDA issues finalized guidelines for use of in vitro diagnostics in oncology drug trials and warnings on vaping; new findings report patients bear more costs when MBC treatment is not concordant with NCCN guidelines.
NCCN Updated Guideline Adds Treatment Options for HER2-Positive Breast Cancer, Emphasizing CDK4/CDK6 Inhibition in Hormone-Sensitive Disease
At the 2018 NCCN conference, Sharon H. Giordano, MD, MPH, FASCO, Professor of Medicine, Department of Breast Medical Oncology, M.D. Anderson Cancer Center, Houston, provided an update on the treatment of patients with HER2-positive breast cancer, noting an “explosion of new therapies” in recent years that have had a tremendous impact on survival.
Somatostatin analogs have multiple roles in the treatment of neuroendocrine tumors (NETs), including the management of symptoms of hormone hypersecretion and, more recently, slowing tumor progression.
An infusion-related reaction documentation tool and grading system and its integration into the electronic health record (EHR) is expected to better identify patients at risk for future reactions, and improve communication among oncology team members.
Compliance with orders for granulocyte colony-stimulating factors (G-CSFs) is suboptimal, and inadequate prophylaxis was directly tied to hospital admissions, according to results of a recent clinical trial from the University of Pennsylvania Health System.
A pharmacist-led outreach program at Magellan Rx Management improved adherence to tyrosine kinase inhibitors (TKIs), and compliance with polymerase chain reaction (PCR) testing in patients with chronic myeloid leukemia (CML).
Results 1 - 6 of 6